Clinical Trial: Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403266) titled 'Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)' on Feb. 04.

Brief Summary: 1. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.

Study Start Date: June 01, 2024

Study Type: INTERVENTIONAL

Condition: Tuberous Sclerosis Complex (TSC)

Intervention: DRUG: YCJ-01 Full Spectrum cannbis Extract

Ful Spectrum cannabis extra...